Elotuzumab is approved for the treatment of multiple myeloma and functions primarily via antibody-dependent cellular cytotoxicity, but has also been shown to have SLAMF7 agonistic activity [62]. The gene discussed is SLAMF7; the disease is AL amyloidosis.